Quick Answer
Editas Medicine, Inc. reported Revenue (ASC 606) of $40.52 million for fiscal year 2025.
Editas Medicine, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $40.52M | +25.4% |
| 2024 | $32.31M | -58.6% |
| 2023 | $78.12M | +296.3% |
| 2022 | $19.71M | -22.8% |
| 2021 | $25.54M | -71.8% |
| 2020 | $90.73M | +341.9% |
| 2019 | $20.53M | -35.7% |
| 2018 | $31.94M | +132.6% |
| 2017 | $13.73M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.54M | +12265.6% | +110.8% |
| June 30, 2025 | $3.58M | +597.5% | -23.2% |
| March 31, 2025 | $4.66M | +310.4% | +7536.1% |
| September 30, 2024 | $61.0K | -98.9% | -88.1% |
| June 30, 2024 | $513.0K | -82.2% | -54.8% |
| March 31, 2024 | $1.14M | -88.5% | -78.7% |
| September 30, 2023 | $5.34M | +12604.8% | +84.8% |
| June 30, 2023 | $2.89M | -54.6% | -70.7% |
- Editas Medicine, Inc. showed an increase of +25.4% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2017–2025 period, Editas Medicine, Inc.’s revenue (asc 606) has grown by 195.2% (from $13.73 million to $40.52 million).
- The most recent figure is from Editas Medicine, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: